I'm taking a new drug from Thailand - V1 Immunitor - and wanted to share the
info with you all as well as my sparkling personality. I have been taking V1
for three months now and although its early days yet, I'm experiencing
renewed energy and vitality, my bloods, particularly LFT's have leveled off
and for the first time in two years my anemia problem seems to have
vanished.
When I first made contact with Immunitor Co. they sent me the first three
months free to trial, to continue on this drug will cost me US $250.00, In
my economy that represents a months income for me and places the drug out of
my reach. I am yet to negotiate my continuance on this personal trial at a
cost that I can afford. Its a bizzare situation where my govt. will fund me
to take HAART but will give me no flexibility to participate in V1. I want
to stop HAART but with no alternative treatment I have concerns for my long
term health.
Any ideas or thoughts in relation to this drug would be welcome. I've
reproduced an email from Immunitor below. Some updated info on my state of
health can be found at:
http://www.users.bigpond.com/papapalya
This personal website has links & further info. I have commenced (June) the
V1 trial and am currently taking one V1 capsule per day in addition to my
PI's and have had no side-effects so far (fingers crossed!). I will be
getting bloods done monthly and will forward details as they develop at your
request. This trial is self-funded and undertaken of my own free will. My
goal is to eliminate the need for higher quantities of PI's.
Your comments and opinions would be very much appreciated. Thanks. Feel free
to call me +61 02 6687 9668.
Regards, Steve Meyer
---
LINKS:
http://www.2bangkok.com/2bangkok/v-1.shtml
http://lists.indymedia.org/mailman/p...er/001697.html
http://www.ejbiotechnology.info/cont...1/full/3/3.pdf
EMAIL FROM IMMUNITOR:
Immunitor publishes article on affordable AIDS drugs
Immunitor Corporation A Thai biotech company- announces publication of
'Low-cost anti-HIV compounds: Potential application for AIDS therapy
1419-1431, 2003). The abstract of the paper can be found on the PubMed
website of the National Library of Medicine
(http://www.ncbi.nlm.nih.gov/entrez/q...=PubMed&list_u
ids=12769722&dopt=Abstract).
The essential elements of this paper were first presented last year at IAEN
symposium: 'Economics of HIV/AIDS in Developing Countries', which was held
during 14th International AIDS conference in Barcelona, in July 2002
(www.iaen.org/files.cgi/7014_Bourinbaiar.pdf). IAEN or International AIDS
Economics Network is a multinational NGO which focuses on affordable
HIV/AIDS prevention and treatment, by providing data, tools, and analysis
for researchers and policymakers working to define and implement
cost-effective AIDS policy.
Considerable progress has been made in recent years in the field of drug
development against HIV. However, the current cost of AIDS drugs is the main
obstacle that prevents their use in developing countries, where 98% of
HIV-infected patients reside. The average yearly price of AIDS therapy and
related health care of affected patients in industrialized countries runs as
high as $22,000 per patient, an amount that corresponds to the combined
income of as
many as one thousand individuals in developing countries. Even in these
countries (increasingly the west) patients without medical insurance cannot
afford the costly therapy. From the beginning it was clear that the most
feasible and economic
means of reaching this goal is to identify anti-HIV drugs among already
available and preferably over-the-counter pharmaceuticals, which have
historically been used for unrelated clinical purposes. Immunitor's paper
summarizes its own original research relating to development and discovery
of an affordable and potentially promising AIDS drugs. The anti-HIV activity
of
drugs and immunomodulating substances such as warfarin, cimetidine,
levamisole, acetaminophen, gramicidin, and V-1 Immunitor (an oral AIDS
vaccine also known as V1) are described and discussed in relation to their
clinical application.
President of Immunitor, pharmacologist Vichai Jirathitikal, noted that 'the
publication of this landmark paper coincides with the 2nd anniversary of the
public launch of V1 in Thailand. The first mass-distribution took place on
June 2, 2001 at Thai-Japan stadium in Bangkok. On that historic day we gave
V1 to 4,000 people. During summer and fall of 2001 we have treated
free-of-charge 40,000 AIDS patients. Today, over 65,000 patients in more
than 60 countries, including 26 countries in Africa, have benefited from our
relentless effort. We have been and still are facing the resistance to our
work. It is difficult to be a pioneer in this highly competitive field of
billion dollar patents that keep only 2% of the world aids population well.
If you are from a third world country. multi-national pharmesuetical
companies
dont really care about you.
Nevertheless despite difficulties and lack of public funds we were able to
publish our clinical data in several peer-reviewed international journals
and this publication is
another proof that a small company like ours can make the difference on
global AIDS crisis. For further information please write to :
info@immunitor.com
--
"NO MAN IS AN ISLAND, entire of itself; every man is a piece of the
continent, a part of the main. If a clod be washed away by the sea, Europe
is the less, as well as if a promontory were, as well as if a manor of thy
friend's or thine own were: any man's death diminishes me, because I am
involved in mankind, and therefore never send to know for whom the bell
tolls; it tolls for thee."
---
Outgoing mail is certified Virus Free.
Checked by AVG anti-virus system (http://www.grisoft.com).
Version: 6.0.525 / Virus Database: 322 - Release Date: 9/10/03
